Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function
Status:
Completed
Trial end date:
2015-07-13
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of oral
bictegravir (formerly GS-9883) in adults with impaired renal function relative to matched,
healthy controls with normal renal function. Each participant in the renal impairment groups
will be matched for age (± 10 years), gender, and body mass index [BMI (± 20%, 18 ≤ BMI ≤ 40
kg/m^2)] with a participant in the control group.